JP2003528144A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003528144A5 JP2003528144A5 JP2001570263A JP2001570263A JP2003528144A5 JP 2003528144 A5 JP2003528144 A5 JP 2003528144A5 JP 2001570263 A JP2001570263 A JP 2001570263A JP 2001570263 A JP2001570263 A JP 2001570263A JP 2003528144 A5 JP2003528144 A5 JP 2003528144A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- substance
- carboxy
- primary headache
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000018238 Primary Headache disease Diseases 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 8
- 150000001335 aliphatic alkanes Chemical class 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 239000002464 receptor antagonist Substances 0.000 description 6
- 229940044551 receptor antagonist Drugs 0.000 description 6
- 206010019233 Headaches Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 102000016979 Other receptors Human genes 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- -1 carboxy, protected carboxy, carbamoyl Chemical group 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000003215 serotonin 5-HT2 receptor antagonist Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2000/001138 WO2001072302A1 (en) | 2000-03-24 | 2000-03-24 | Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003528144A JP2003528144A (ja) | 2003-09-24 |
| JP2003528144A5 true JP2003528144A5 (enExample) | 2007-05-10 |
Family
ID=9883925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001570263A Pending JP2003528144A (ja) | 2000-03-24 | 2000-03-24 | 頭痛治療のためのプロスタノイドｅｐ４受容体アンタゴニストの使用およびそのアンタゴニストについてのアッセイ |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1267867B1 (enExample) |
| JP (1) | JP2003528144A (enExample) |
| AT (1) | ATE395058T1 (enExample) |
| AU (2) | AU2000234451B2 (enExample) |
| CA (1) | CA2402099C (enExample) |
| DE (1) | DE60038902D1 (enExample) |
| DK (1) | DK1267867T3 (enExample) |
| WO (1) | WO2001072302A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005511562A (ja) * | 2001-10-31 | 2005-04-28 | メディカル リサーチ カウンシル | 月経困難症及び月経過多の治療のためのプロスタグランジンレセプターｅｐ２及び／又はｅｐ４のアンタゴニスト |
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| AU2008221194B2 (en) * | 2007-02-26 | 2013-06-27 | Merck Canada Inc. | Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists |
| US20150126573A1 (en) | 2012-05-09 | 2015-05-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| WO2018210992A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| AU2018268311B2 (en) | 2017-05-18 | 2022-02-10 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as PGE2 receptor modulators |
| EP3625224B1 (en) | 2017-05-18 | 2021-08-04 | Idorsia Pharmaceuticals Ltd | N-substituted indole derivatives |
| US11325899B2 (en) | 2017-05-18 | 2022-05-10 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators |
| WO2018210994A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Phenyl derivatives as pge2 receptor modulators |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2179399A1 (en) * | 1993-12-20 | 1995-06-29 | Kiyoshi Taniguchi | 4,5-diaryloxazole derivatives |
| AUPO713297A0 (en) * | 1997-06-02 | 1997-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compound |
| GB9720270D0 (en) * | 1997-09-25 | 1997-11-26 | Pharmagene Lab Limited | Medicaments for the treatment of migraine |
| ES2274378T3 (es) * | 1999-08-10 | 2007-05-16 | Glaxo Group Limited | Ligando del receptor ep4 y uso contra dolor neuropatico, cancer de colon,hiv y migraña. |
-
2000
- 2000-03-24 AU AU2000234451A patent/AU2000234451B2/en not_active Ceased
- 2000-03-24 JP JP2001570263A patent/JP2003528144A/ja active Pending
- 2000-03-24 CA CA2402099A patent/CA2402099C/en not_active Expired - Fee Related
- 2000-03-24 DK DK00912807T patent/DK1267867T3/da active
- 2000-03-24 EP EP00912807A patent/EP1267867B1/en not_active Expired - Lifetime
- 2000-03-24 DE DE60038902T patent/DE60038902D1/de not_active Expired - Lifetime
- 2000-03-24 WO PCT/GB2000/001138 patent/WO2001072302A1/en not_active Ceased
- 2000-03-24 AU AU3445100A patent/AU3445100A/xx active Pending
- 2000-03-24 AT AT00912807T patent/ATE395058T1/de not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU760735B2 (en) | A method for treating inflammatory diseases by administering a thrombin inhibitor | |
| TWI432417B (zh) | 充當生長激素促分泌素受體之格琳（Ｇｈｒｅｌｉｎ）類似物配體的新穎三唑衍生物 | |
| SK13952002A3 (sk) | Farmaceutická kompozícia na liečenie akútnej, chronickej a/alebo neuropatickej bolesti a migrén | |
| CA2813648C (en) | Combinations of serotonin receptor agonists for treatment of movement disorders | |
| JP2004511466A5 (enExample) | ||
| JP2009536220A5 (enExample) | ||
| JP2002533407A (ja) | 新形成の治療におけるマトリクスメタロプロテイナーゼ阻害剤とインテグリン拮抗剤の使用 | |
| TW202327569A (zh) | 包含ｔｅａｄ抑制劑的藥物組合及其用於癌症治療之用途 | |
| JP2006503850A5 (enExample) | ||
| JP2003528144A5 (enExample) | ||
| JP2012255039A (ja) | ニコチン性アセチルコリンα７受容体アゴニストの組合せ剤 | |
| JP2003519228A5 (enExample) | ||
| EA200700027A1 (ru) | Антагонисты рецептора глюкагона, их получение и терапевтическое применение | |
| JP2012522805A5 (enExample) | ||
| JP5642892B2 (ja) | 多形膠芽腫の治療のためのマシテンタンを含有する組み合わせ剤 | |
| CA2402099A1 (en) | Methods for the treatment of primary headache disorders using prostanoid ep4 receptor antagonists, and assays for agents for such treatment | |
| JP2000198734A (ja) | 胃運動性減弱および関連疾患の治療のための運動性増強薬 | |
| JP2003510355A (ja) | 精神障害におけるｎｋ１レセプターアンタゴニストとｇａｂａ類縁体との共働的組合せ体の使用 | |
| JP2002121153A (ja) | 抑うつ及び不安のための併合療法 | |
| JPH06500099A (ja) | Ｃｎｓ疾病の処置におけるヘテロ環状アミノ―アルコール化合物の使用 | |
| JP2007516292A5 (enExample) | ||
| JP2004533986A5 (enExample) | ||
| EA015483B1 (ru) | ПРИМЕНЕНИЕ ИНГИБИТОРА p38 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ | |
| KR20210062023A (ko) | Crac 억제제 및 코르티코스테로이드를 포함하는 조성물 및 그의 사용 방법 | |
| JP2008501632A5 (enExample) |